Bryce Point Capital, LLC Krystal Biotech, Inc. Transaction History
Bryce Point Capital, LLC
- $118 Billion
- Q2 2025
A detailed history of Bryce Point Capital, LLC transactions in Krystal Biotech, Inc. stock. As of the latest transaction made, Bryce Point Capital, LLC holds 4,323 shares of KRYS stock, worth $620,869. This represents 0.5% of its overall portfolio holdings.
Number of Shares
4,323
Previous 4,286
0.86%
Holding current value
$620,869
Previous $790 Million
24.75%
% of portfolio
0.5%
Previous 0.59%
Shares
2 transactions
Others Institutions Holding KRYS
# of Institutions
329Shares Held
24.4MCall Options Held
299KPut Options Held
97.6K-
Black Rock Inc. New York, NY3.95MShares$567 Million0.02% of portfolio
-
Vanguard Group Inc Valley Forge, PA2.82MShares$405 Million0.01% of portfolio
-
Avoro Capital Advisors LLC New York, NY2.73MShares$392 Million7.97% of portfolio
-
State Street Corp Boston, MA1.23MShares$176 Million0.01% of portfolio
-
Capital World Investors Los Angeles, CA954KShares$137 Million0.03% of portfolio
About Krystal Biotech, Inc.
- Ticker KRYS
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 25,664,300
- Market Cap $3.69B
- Description
- Krystal Biotech, Inc., a clinical stage biotechnology company, engages in the field of redosable gene therapy to treat serious rare diseases in the United States. Its lead product candidate is beremagene geperpavec (B-VEC), which is in Phase III clinical study to treat dystrophic epidermolysis bullosa. The company is also involved in developing ...